Melanotan I vs Melanotan II
Melanotan I and Melanotan II share a name, a mechanism category, and a nickname ("the tanning peptide") — but they are fundamentally different drugs with dramatically different safety profiles. One is FDA-approved with 1,000+ patients treated and zero melanoma events. The other is unapproved everywhere, widely sold on the gray market, and linked to documented melanoma case reports. Confusing them is a costly mistake.
Melanotan I
An FDA-approved selective MC1R agonist for erythropoietic protoporphyria (EPP). Stimulates protective eumelanin production without the broad side effects of Melanotan II.
Melanotan II
A synthetic melanocortin peptide studied for tanning, sexual function, and appetite suppression. Not FDA-approved; the FDA has issued public warnings against its use.
| Category | Melanotan I | Melanotan II |
|---|---|---|
| FDA Approval | Yes — approved 2019 as Scenesse for erythropoietic protoporphyria (EPP) | No — never approved in any country, banned as a cosmetic ingredient in multiple jurisdictions |
| Receptor Selectivity | Selective for MC1R (tanning receptor) with minimal activity at MC3R/MC4R | Non-selective — activates MC1R, MC3R, MC4R, and MC5R |
| Structure | 13-amino acid linear analog of alpha-MSH (Nle4, D-Phe7-α-MSH) | 7-amino acid cyclic lactam analog (smaller, more stable, non-selective) |
| Delivery | Subcutaneous bioresorbable implant (16mg) every 60 days — administered by healthcare professional | Self-administered injection or nasal spray (gray market) — no medical oversight |
| Safety Database | 1,000+ patients in clinical trials and post-marketing; zero melanoma events in 10+ years of use | Multiple case reports of melanoma development; all cases involved pre-existing risk factors |
| Mole Changes | Only 2 new nevi reported in 115 patients over 8 years | Darkens and alters existing moles uniformly — interferes with melanoma screening |
| Sexual/Cardiovascular Side Effects | Minimal — selectivity avoids MC4R activation | Spontaneous erections, flushing, nausea, increased libido via MC4R (this is how PT-141 was discovered) |
| Other Side Effects | Implant site reactions, mild headache, nausea (generally mild) | Nausea, fatigue, darkening of existing moles, reports of cerebral edema and kidney dysfunction |
| Cost & Access | Expensive ($10,000+/implant), restricted distribution for EPP only | Cheap ($30-100 per vial on gray market), widely available online despite illegality |
| Regulatory Warnings | FDA-approved with standard monitoring protocols | FDA warning letters, Australian TGA consumer alert, UK Medicines Regulator warning |
| Common Discussion Context | Clinical EPP treatment; rare dermatology indications | Cosmetic tanning, TikTok nasal sprays, gray-market self-use |
Summary
The most important distinction between Melanotan I and Melanotan II is receptor selectivity. MC1R activation is inherently photoprotective — it promotes DNA repair and eumelanin (protective pigment) production. People with loss-of-function MC1R variants have 2-4x higher melanoma risk; pharmacologically activating MC1R should reduce risk, not increase it. Melanotan I (afamelanotide/Scenesse) validates this: in 1,000+ patients treated over a decade, zero melanoma events have been reported. Melanotan II is a different story. Its non-selectivity causes the spontaneous erections and nausea that make it infamous (MC4R), and its widespread gray-market use — often combined with UV exposure to "activate" the tan — creates genuine risks. The melanoma case reports in MT-II users are debated: are they caused by MT-II, or detected earlier because users notice mole changes, or simply coincidental in patients with heavy UV exposure? What's not debated is that MT-II darkens moles uniformly, making melanoma screening harder, and that TikTok nasal sprays carry additional contamination risks. For patients with EPP, afamelanotide is a life-changing approved medication. For cosmetic tanning, the regulatory gap between demand and supply is real — but MT-II from a gray-market vendor isn't the answer. The cosmetic tanning market is waiting for a selective MC1R agonist to fill this gap safely; afamelanotide could theoretically do it, but pharmaceutical economics of an expensive implant don't favor cosmetic indications.